·
ADARx Pharmaceuticals set the terms of its United States listing on a day when a consumer health company launched a heavily secondary-weighted deal. Two different tests of the same reopening.
ADARx Pharmaceuticals is targeting a valuation of up to $1.74 billion in its United States initial public offering, in a deal being read as evidence of strengthening investor appetite for biotechnology listings.
The number matters less than the category. Biotechnology has been the most closed corner of the new-issue market for the better part of two years, for a structural reason: the sector's listings are almost entirely pre-revenue, which means they price off clinical probability and rate expectations rather than off earnings. Higher long-end yields hit those valuations harder than almost any other equity, and the Federal Reserve raised rates again on with projections implying more to come.
A biotechnology company setting a valuation target above $1.5 billion into that backdrop is either a company with unusually strong clinical data or a signal that the window has reopened despite the rate path.
The same day, a different test
Oura launched its own offering on Monday with a range of $40.00 to $44.00 a share, in a deal where 36.5 million of the 50 million base shares come from existing holders and the entire overallotment option is secondary.
The two deals test different things. A pre-revenue biotechnology listing tests whether public investors will fund clinical development at a price the private round holders can accept. A heavily secondary consumer listing tests whether public investors will absorb private holders' inventory at all.
Both are questions the private markets fundraising cycle needs answered. Distributions to limited partners have been the binding constraint on the whole asset class for two years, and the exit window is the mechanism that relieves it.
What remains unknown
The prospectus terms have not been detailed publicly beyond the valuation target. Share count, price range, use of proceeds, existing shareholder composition, pipeline stage and lead indication all sit in the filing rather than in the valuation headline, and the valuation target itself is an objective rather than a price.
What to watch
Pricing for both deals, and specifically where each prints relative to its range. Two deals in different sectors pricing at or above their ranges in the same week would be the strongest evidence in months that the fourth-quarter listing calendar is viable. Either pricing below would be read as a false start, and the calendar behind them would thin out accordingly.